By Chemical Treatment Patents (Class 435/238)
  • Publication number: 20090005334
    Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and uses of the compound, particularly in antisense therapy.
    Type: Application
    Filed: February 19, 2008
    Publication date: January 1, 2009
    Applicant: Bio-Rad Laboratories Inc.
    Inventor: David Segev
  • Publication number: 20080306061
    Abstract: The present invention concerns substituted aminophenylsulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.
    Type: Application
    Filed: November 28, 2006
    Publication date: December 11, 2008
    Inventors: Herman Augustinus De Kock, Tim Hugo Maria Jonckers, Stefaan Julien Last, Paul Jozef Gabriel Maria Boonants, Dominique Louis Nestor Ghislain Surleraux, Piet Tom Bert Paul Wigerinck
  • Publication number: 20080299131
    Abstract: The invention provides a composition comprising for simultaneous, sequential or separate administration a) a polyanion; and b) an antibody reactive against an antigen on the surface of an intracellular form of a virus, which virus has an extracellular form that is surrounded by one lipid membrane more than the intracellular form. The present inventors have found that the compositions according to the invention comprising an antibody and a polyanion can neutralize virus infectivity more efficiently than other compositions reported hitherto.
    Type: Application
    Filed: June 28, 2005
    Publication date: December 4, 2008
    Inventors: Geoffrey Lilley Smith, Gemma Chevonne Carter, Mansun Law, Michael Stanley Hollinshead
  • Publication number: 20080292653
    Abstract: Classical swine fever virus is a world-wide distributed highly-contagious disease affecting swine. The two main strategies for diseases control are prophylactic vaccination and non-vaccination stamping out policies. Marker vaccines are a promising strategy. Here we report the rational development of a doubly antigenic marker CSFV experimental live attenuated candidate strain vaccine (Flag/T4 virus). Flag/T virus (Flag/T4v) is based in the combination of two Brescia derived recombinant attenuated viruses: RB-C22 and T4. RB-C22v contains a 19mer insertion in the structural glycoprotein E1, while T4v posses mutated CSFV amino acid residues 830 to 834 in the structural glycoprotein E2, deleting the highly conserved epitope recognized by monoclonal antibody (mAb) WH303. Flag/T4 virus contains a positive foreign antigenic marker, due to the insertion of the highly antigenic epitope Flag in the 19mer insertion of E1, as well as a negative antigenic marker, the lack of reactivity with mAb WH303.
    Type: Application
    Filed: May 22, 2007
    Publication date: November 27, 2008
    Inventors: Manuel V. Borca, Guillermo R. Risatti
  • Publication number: 20080286849
    Abstract: The invention relates to the herbal extract having anti-viral activity. More specifically, it relates to the herbal extract produced by extracting the comminuted Fructus Ligustri Lucidi (privet fruit), Rhizoma Polygonati (sealwort), Herba Agrimoniae (agrimonia), Radix Rehmanniae Glutinosae Conquitae (steamed glutinous rehmannia) or the mixture thereof, with a low polar solvent, and to the method for in vitro antagonizing virus by contacting the herbal extract with viruses.
    Type: Application
    Filed: July 29, 2008
    Publication date: November 20, 2008
    Applicant: Industrial Technology research institute
    Inventors: Li-Ching Lo, Lien-Tai Chen
  • Publication number: 20080274534
    Abstract: The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide).
    Type: Application
    Filed: July 15, 2008
    Publication date: November 6, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Jesper Christensen, Erik Halkjaer, Turid Preuss, Thomas Budde Hansen, Lene Vaedele Madsen Tomoda, Nina Johansen
  • Publication number: 20080227774
    Abstract: The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: March 14, 2008
    Publication date: September 18, 2008
    Inventors: Frank Ruebsam, Peter Dragovich
  • Patent number: 7425437
    Abstract: The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 16, 2008
    Assignee: Crucell Holland B.V.
    Inventors: Alphonsus G. C. M. UytdeHaag, Govert Johan Schouten, Jaap Goudsmit
  • Publication number: 20080214529
    Abstract: The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: December 12, 2007
    Publication date: September 4, 2008
    Inventors: Frank Ruebsam, Zhongxiang Sun, Benjamin Ayida, Yuefen Zhou, Alan X. Xiang
  • Publication number: 20080206742
    Abstract: Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 28, 2008
    Inventor: Ganjam V. Kalpana
  • Patent number: 7413889
    Abstract: The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have are useful as antigens for inducing the production of antibodies having desired binding properties, e.g., protective antibodies, or for use as vaccine antigens for the induction of protective immunity against the parvovirus. Feline parvovirus epitopes were fused to the N-terminus of the TMV coat protein, expressed in Nicotiana plants, extracted, purified, characterized and administered to animals, resulting in protective immunity.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: August 19, 2008
    Assignee: Kentucky Bioprocessing, LLC
    Inventors: Gregory P. Pogue, John A. Lindbo, Michael J. McCulloch, Jonathan E. Lawrence, Cynthia S. Gross, Stephen J. Garger
  • Publication number: 20080193413
    Abstract: Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    Type: Application
    Filed: April 4, 2008
    Publication date: August 14, 2008
    Inventors: Douglas K. Hutchinson, John R. Bellettini, David A. Betebenner, Richard D. Bishop, Thomas B. Borchardt, Todd D. Bosse, Russell D. Cink, Charles A. Flentge, Bradley D. Gates, Brian E. Green, Mira M. Hinman, Peggy P. Huang, Larry L. Klein, Allan C. Krueger, Daniel P. Larson, M. Robert Leanna, Dachun Liu, Darold L. Madigan, Keith F. McDaniel, John T. Randolph, Todd W. Rockway, Teresa A. Rosenberg, Kent D. Stewart, Vincent S. Stoll, Rolf Wagner, Ming C. Yeung
  • Publication number: 20080188466
    Abstract: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 26, 2007
    Publication date: August 7, 2008
    Inventors: Peter Dragovich, Yuefen Zhou, Stephen E. Webber
  • Publication number: 20080184618
    Abstract: Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses. Accordingly, provided herein are methods of inactivating a virus and methods of treating a viral infection. Methods of delivering a therapeutic agent to a mammalian subject and methods of inactivating a virus in the gastrointestinal tract of an animal are also provided.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 7, 2008
    Inventors: Jerald W. Darlington, John Hughes, Panayiotis P. Constantinides, Mingming Fang, Jason H. St. Onge
  • Publication number: 20080175862
    Abstract: The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.
    Type: Application
    Filed: April 24, 2006
    Publication date: July 24, 2008
    Applicant: Acambis Inc.
    Inventors: Konstantin V. Pugachev, Farshad Guirakhoo, Thomas P. Monath
  • Publication number: 20080175864
    Abstract: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HVC release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.
    Type: Application
    Filed: January 24, 2007
    Publication date: July 24, 2008
    Inventors: Jin Ye, Fang Sun, Hua Huang, Michael J. Gale
  • Publication number: 20080139465
    Abstract: A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to obtain pharmaceutical grade API on a commercial scale is provided. The API produced by the process is highly pure (at least 90% API out of the total protein) and highly active (at least 90% active API). Pharmaceutical compositions comprising the purified API and methods of using same are also described.
    Type: Application
    Filed: June 23, 2005
    Publication date: June 12, 2008
    Applicant: KAMADA LTD.
    Inventor: Shabtai Bauer
  • Publication number: 20080125444
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: June 6, 2007
    Publication date: May 29, 2008
    Inventors: Ying Sun, Yat Sun Or, Zhe Wang
  • Publication number: 20080108129
    Abstract: Methods for obtaining modified proteins or virus with an intact native binding site and decreased antigenicity and modified proteins or virus obtainable by said methods are provided. The methods of protein or virus modification comprise masking with non-immunogenic molecules the protein or the virus surface, except for the protein or the virus binding site. Examples of modified proteins or virus that can be modified in accordance to the methods include polyclonal or monoclonal antibodies, modified replication-defective virus, hormones, and enterotoxins.
    Type: Application
    Filed: December 29, 2005
    Publication date: May 8, 2008
    Applicant: Gavish-Galillee Bio Applications Ltd.
    Inventors: Jacob Pitcovski, Jacob Vaya
  • Publication number: 20080096959
    Abstract: Contemplated compositions and methods include a catechin at a concentration effective to inactivate SARS at least by a factor of 2 log 10 units when the formulation is applied to a surface. Preferably, the catechins are provided as a complex mixture, and most preferably as a near-native catechin preparation from green tea.
    Type: Application
    Filed: July 5, 2005
    Publication date: April 24, 2008
    Applicant: MITSUI NORIN CO., LTD.
    Inventors: Yukihiko Hara, Paul T. Wegener
  • Patent number: 7354190
    Abstract: A two-stage mixing system, apparatus, and method produces a solution including a first substance and a second substance in a predetermined ratio by first mixing the first substance with a first liquid to produce a first solution and then mixing the first solution with the second substance to produce a second solution. Multiple batches of second solution may be produced from a single batch of first solution. Multiple batches of second solution may be produced in parallel.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: April 8, 2008
    Assignee: DEKA Products Limited Partnership
    Inventors: Jason A. Demers, Matthew C. Harris, David W. McGill, Larry B. Gray, Edward J. Staub
  • Publication number: 20080076115
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2004
    Publication date: March 27, 2008
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Publication number: 20080044807
    Abstract: A method of treating samples containing hepatitis C virus (HCV) which method comprises treating HCV-containing samples with a treating agent containing (1) an acidifying agent, and (2) a protein-denaturing agent, or an amphoteric surfactant or a cationic surfactant having both a straight chain alkyl group of 10 or more carbon atoms and a tertiary amine or a quaternary ammonium salt in the same molecule, to effect the release of the HCV antigen and the inactivation of antibodies that bind to the HCV antigen, and the like.
    Type: Application
    Filed: October 28, 2004
    Publication date: February 21, 2008
    Applicant: Advanced Life Science Institute, Inc.
    Inventors: Katsumi Aoyagi, Kumiko Iida, Naoko Matsubara
  • Publication number: 20070185216
    Abstract: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.
    Type: Application
    Filed: February 1, 2007
    Publication date: August 9, 2007
    Inventors: MARCIA SNYDER, David R. Macinga, James W. Arbogast
  • Patent number: 7223410
    Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using ?-propiolactone, a non-ionic detergent, particularly n-octyl-?-D-glucopyranoside and n-octyl-?-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: May 29, 2007
    Assignee: Sanofi Pasteur Limited
    Inventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein
  • Patent number: 7129223
    Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: October 31, 2006
    Assignee: The University of HongKong
    Inventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
  • Patent number: 7094378
    Abstract: Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value; mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: August 22, 2006
    Assignee: Gambro, Inc.
    Inventors: Raymond Paul Goodrich, Jr., Dennis Hlavinka
  • Patent number: 7056507
    Abstract: An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided. An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: June 6, 2006
    Assignee: Kaneka Corporation
    Inventors: Eiji Ogino, Michio Nomura, Takashi Asahi, Shuichi Kaneko, Akito Sakai
  • Patent number: 7048930
    Abstract: The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: May 23, 2006
    Assignee: Innogenetics N.V.
    Inventors: Fons Bosman, Erik Depla, Geert Deschamps, Erwin Sablon, Isabelle Samson, Annie Van Broekhoven, Joost Haelewyn
  • Patent number: 7037642
    Abstract: Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 2, 2006
    Assignee: Cerus Corporation
    Inventor: Derek J. Hei
  • Patent number: 7033813
    Abstract: Presented herein is a description for the manufacturing of inactivated HIV for use in vaccines against AIDS, as well as other inactivated viruses for other infectious diseases. This invention incorporates methods for inactivating infectious virus particles while retaining protein integrity and antigenicity. The methods utilize critical, near-critical or supercritical fluids with or without polar cosolvents. This invention would allow for the creation of HIV vaccines from genetically attenuated HIV strains for a greater degree of product safety, and from combinations of different HIV strains for broader protection. This HIV vaccine manufacturing technology is inexpensive, amenable to large-scale processing and portable, i.e. it can be readily implemented in a host country site. This invention can be utilized for other viral and bacterial infectious diseases, such as influenza and hepatitis.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: April 25, 2006
    Inventors: Trevor P Castor, Petr O. Ilyinskii, Lisa Lallos
  • Patent number: 7026154
    Abstract: The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between ?5° C. and +50° C. and at a pH of between about 5 and 9. Its subject is also a method of preparing a viral preparation comprising such a method of inactivation. The invention also relates to a viral preparation obtained according to the method of the invention. Finally, it relates to a host cell and a composition comprising such a viral preparation as well as their uses for therapeutic or prophylactic purposes.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: April 11, 2006
    Assignee: Transgene S.A.
    Inventors: David Gaillac, Michel Koehl
  • Patent number: 7008784
    Abstract: The present invention is directed toward methods for the production of non-infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-like particles. These particles are prepared from a recombinant expression vector comprising a heterologous promoter operatively connected to a DNA molecule comprising a modified HIV genome devoid of the long terminal repeat (LTR) regulatory regions but containing at least the gag and pol genes in their natural genomic arrangement. This vector is introduced into mammalian cells to produce the particles of interest. These particles should prove useful in a number of diagnostic, virologic, and immunologic applications.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: March 7, 2006
    Assignee: Aventis Pasteur Limited
    Inventors: Joel Haynes, Michel Henri Klein, Benjamin Rovinski, Shi Xian Cao
  • Patent number: 6991899
    Abstract: The invention provides cell lines which are useful for the rapid detection and production of influenza and parainfluenza viruses. In particular, the invention relates to transgenic mink lung cells which show increased sensitivity to infection by influenza A, influenza B, or parainfluenza 3 viruses, or which are capable of enhanced productivity of infectious virions. The invention is suitable for use in culturing clinical influenza and parainfluenza virus isolates and for the production of influenza and parainfluenza virus for vaccine formulations, as antigen preparations for diagnostic applications, and for screening antiviral drugs.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: January 31, 2006
    Assignee: University Hospitals of Cleveland
    Inventor: Yung T. Huang
  • Patent number: 6989263
    Abstract: The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: January 24, 2006
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Louis E. Henderson, Larry O. Arthur, William G. Rice
  • Patent number: 6967239
    Abstract: Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: November 22, 2005
    Assignee: Laboratoire Francias du Franctionnement et des Biotechnologies
    Inventors: Abdessatar Chtourou, Michel Nogre, Pierre Porte
  • Patent number: 6951713
    Abstract: Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 1 ?m to about 200 ?m. The matrix can be fibrous, and the particles can have a surface area greater than 750 m2/g and a pore diameter between about 25 and 800 ?. The device can be used to adsorb and remove a pathogen-inactivating compound that is a nucleic acid-binding compound such as psoralen, an acridine derivative or a dye from a biological composition such as a blood product.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: October 4, 2005
    Assignee: Cerus Corporation
    Inventors: Derek J. Hei, Michael S. Clarke
  • Patent number: 6893856
    Abstract: Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source containing these components is subjected to a appropriate separation procedures, especially by using membrane-chromatographic methods.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 17, 2005
    Assignee: Octapharma AG
    Inventors: Djuro Josic, Ales Strancar
  • Patent number: 6838080
    Abstract: The present disclosure provides methods and compositions for inducing an immune response to an antigen, especially in an immunogenic composition comprising sialic acid where the antigen comprises sialic acid and wherein the immunogenic composition further comprises a sialic acid binding component, e.g., an inactivated or attenuated paramyxovirus or orthomyxovirus such as an influenza virus comprising a sialic acid binding component, e.g., a neuraminidase. The compositions comprising sialic acid and a sialic acid binding component effectively induce a humoral immune response even in a human or animal which is deficient in CD4+ T cells, due to a disease such as ARC or AIDS, and there is also an immunoglobulin class switching even in the absence of CD4+ T cells.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: January 4, 2005
    Assignee: Emory University
    Inventors: Richard W. Compans, Zhiyi Sha
  • Patent number: 6825027
    Abstract: The present invention provides methods of purification of Hepatitis A Virus from the supernatant of an infected cell culture and production of a preparation of purified HAV antigen. The present invention is also directed to an HAV vaccine composition comprising a preparation consisting of purified mature HAV particles in an amount sufficient to induce a protective immune response in a mammal.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: November 30, 2004
    Assignee: Baxter Healthcare S.A.
    Inventors: Christa Tauer, Heidi Meyer, Artur Mitterer, Noel Barrett
  • Patent number: 6808916
    Abstract: The present invention is directed to a method of extracting virus, particularly reovirus, from a culture of cells. Infectious virus can be extracted from the culture with a detergent at a convenient temperature such as 25° C. or 37° C. to produce high virus titers. Both ionic and non-ionic detergents can be used in the present invention.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: October 26, 2004
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson
  • Patent number: 6805870
    Abstract: Multipotent paramunity inducers are described which are based on combinations of poxvirus components derived from various poxviruses with paramunizing properties and which have been improved in terms of their potency and their paramunization-related activities as compared with the known paramunity inducers. The invention also relates to a method for preparing these multipotent paramunity inducers and to their use as drugs.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: October 19, 2004
    Inventor: Anton Mayr
  • Patent number: 6803041
    Abstract: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 12, 2004
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Mark W. Mellencamp
  • Patent number: 6800432
    Abstract: A method and apparatus for inactivating viruses in a body fluid. A mixture including a therapeutically effective amount of methylene blue and an amount of a body fluid is formed in a container under sterile conditions and then the container is irradiated with a light field of a suitable intensity and wavelength for activating the methylene blue for a time sufficient to inactivate viruses in the mixture. The mixture is maintained in a substantially static state within the container.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: October 5, 2004
    Assignee: Baxter International Inc.
    Inventors: Ludwig Wolf, Jr., William Bratten, John Foley
  • Patent number: 6720136
    Abstract: Methods of inactivating contaminants of a biological matrix are disclosed. The methods include the steps of: (a) contacting a biological matrix with an inactivating agent including an aziridino moiety, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a solid support including at least 1 quenching moiety attached to the solid support through covalent bonds, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the solid support and the unreacted agent from the biological matrix, where the unreacted agent is attached to the solid support through covalent bonds.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: April 13, 2004
    Assignee: V. I Technologies, Inc.
    Inventors: Andrei A. Purmal, Samuel K. Ackerman
  • Patent number: 6705556
    Abstract: The White Spot Syndrome Virus (WSSV) is a virus affecting shrimps as well as other crustaceans, and the WSSV epidemic poses a serious threat to the shrimp farming industry. The present invention relates to compositions and methods for inducing tolerance and/or immunity to White Spot Syndrome Virus infections. In one embodiment, the invention provides for a tolerine composition based on inactivated viral particles. In another embodiment, the invention provides for a method for inducing tolerance/immunity in shrimps by exposing larval shrimps to the tolerine composition. In yet another embodiment, the invention provides for tolerine composition with improved purity.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: March 16, 2004
    Assignee: First Republic Corporation of America
    Inventor: Charles Rolland Laramore
  • Patent number: 6660272
    Abstract: The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It relates to purified preparations of these strains, conventional attenuated or inactivated vaccines, recombinant live vaccines, plasmid vaccines and subunit vaccines, as well as reagents and diagnostic methods. It also relates to the DNA fragments which can be used for the production of subunits in an in vitro expression vector or as sequences to be integrated into a virus or plasmid type in vivo expression vector.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: December 9, 2003
    Assignees: Merial, The Queen's University of Belfast, University of Saskatchewan
    Inventors: Gordon Allan, Brian Meehan, Edward Clark, John Ellis, Deborah Haines, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly
  • Patent number: 6660471
    Abstract: This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV sub-genomic replicons. The invention also provides methods of using the cells of the invention to screen for compounds that modulate viral RNA replication, including HCV RNA replication.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: December 9, 2003
    Assignee: Chiron Corporation
    Inventors: Mark Selby, Hui-Hua Lu
  • Patent number: 6653081
    Abstract: This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: November 25, 2003
    Assignee: ViroLogic, Inc.
    Inventor: Jeannette Whitcomb
  • Patent number: RE39494
    Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: February 27, 2007
    Assignee: Intervet Inc.
    Inventors: Gerald R. Fitzgerald, C. Joseph Welter